

# Federica Cavallo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9369855/publications.pdf>

Version: 2024-02-01

174  
papers

8,754  
citations

57631

44  
h-index

49773

87  
g-index

182  
all docs

182  
docs citations

182  
times ranked

10431  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and <sc>anti-CSPG4</sc> vaccination: A retrospective study on 68 cases (2010-2020). Veterinary and Comparative Oncology, 2022, 20, 189-197.	0.8	8
2	Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy. Cells, 2022, 11, 172.	1.8	4
3	Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. Biomedicines, 2022, 10, 230.	1.4	1
4	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research. Frontiers in Veterinary Science, 2022, 9, 803093.	0.9	4
5	Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?. Frontiers in Oncology, 2022, 12, 877384.	1.3	4
6	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. , 2022, 10, e004007.		7
7	Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy. Oncolmmunology, 2022, 11, .	2.1	12
8	Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential. British Journal of Cancer, 2021, 124, 207-216.	2.9	44
9	Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies. Cells, 2021, 10, 108.	1.8	16
10	Evaluation of prognostic impact of pre-treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant <sc>CSPG4</sc>-antigen electrovaccination: an explorative study. Veterinary and Comparative Oncology, 2021, 19, 353-361.	0.8	9
11	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. Cancers, 2021, 13, 894.	1.7	6
12	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Frontiers in Oncology, 2021, 11, 610303.	1.3	118
13	Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant <sc>CSPG4-DNA</sc> electrovaccination: A retrospective study on 155 cases. Veterinary and Comparative Oncology, 2021, 19, 651-660.	0.8	13
14	Targeting the Extracellular HSP90 Co-Chaperone Morgana Inhibits Cancer Cell Migration and Promotes Anticancer Immunity. Cancer Research, 2021, 81, 4794-4807.	0.4	16
15	The Amot/integrin protein complex transmits mechanical forces required for vascular expansion. Cell Reports, 2021, 36, 109616.	2.9	13
16	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs, 2021, 13, 1913791.	2.6	53
17	Canine Melanoma and Osteosarcoma Immunotherapy by Means of In Vivo DNA Electroporation. , 2021, , 277-304.		0
18	Breast cancer stem cell antigens as targets for immunotherapy. Seminars in Immunology, 2020, 47, 101386.	2.7	48

#	ARTICLE	IF	CITATIONS
19	Cancer stem cell antigens as targets for new combined anti-cancer therapies. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 129, 105861.	1.2	12
20	Liver-Specific siRNA-Mediated Stat3 or C3 Knockdown Improves the Outcome of Experimental Autoimmune Myocarditis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 62-72.	1.8	5
21	Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9418.	1.8	32
22	Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. <i>Viruses</i> , 2020, 12, 488.	1.5	43
23	Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1039-1053.	1.6	26
24	Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression. <i>International Journal of Biological Sciences</i> , 2020, 16, 1238-1251.	2.6	19
25	Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1492.	1.7	25
26	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. <i>Vaccines</i> , 2020, 8, 166.	2.1	1
27	Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 131-141.	2.0	37
28	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985549.	1.4	20
29	Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1839-1853.	2.0	34
30	Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 119-188.	0.9	32
31	â€˜In Vitroâ€™, â€˜In Vivoâ€™ and â€˜In Silicoâ€™ Investigation of the Anticancer Effectiveness of Oxygen-Loaded Chitosan-Shelled Nanodroplets as Potential Drug Vector. <i>Pharmaceutical Research</i> , 2018, 35, 75.	1.7	16
32	A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer <i>in vivo</i> . <i>OncolImmunology</i> , 2018, 7, e1408746.	2.1	49
33	Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. <i>OncolImmunology</i> , 2018, 7, e1494108.	2.1	26
34	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	1.8	33
35	Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 1417-1425.	1.6	25
36	Prolongation of survival of dogs with oral malignant melanoma treated by <i>en bloc</i> surgical resection and adjuvant <i>scp</i> CSPG4 <i>scp</i> antigen electrovaccination. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 996-1013.	0.8	42

#	ARTICLE	IF	CITATIONS
37	RNAs competing for microRNAs mutually influence their fluctuations in a highly non-linear microRNA-dependent manner in single cells. <i>Genome Biology</i> , 2017, 18, 37.	3.8	40
38	NK cells control breast cancer and related cancer stem cell hematological spread. <i>Oncolmmunology</i> , 2017, 6, e1284718.	2.1	47
39	The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. <i>Nature Communications</i> , 2017, 8, 14797.	5.8	26
40	The IKK/NF- $\kappa$ B signaling pathway requires Morgana to drive breast cancer metastasis. <i>Nature Communications</i> , 2017, 8, 1636.	5.8	73
41	Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. <i>Vaccines</i> , 2017, 5, 20.	2.1	6
42	In vivo evaluation of tumour acidosis for assessing the early metabolic response and onset of resistance to dichloroacetate by using magnetic resonance pH imaging. <i>International Journal of Oncology</i> , 2017, 51, 498-506.	1.4	57
43	CSPG4: a prototype oncoantigen for translational immunotherapy studies. <i>Journal of Translational Medicine</i> , 2017, 15, 151.	1.8	51
44	Abstract 5572: AX09: an immunotherapy candidate targeting the breast cancer stem cell protein xCT. , 2017, , .		0
45	Protection of mice against the highly pathogenic VVHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity. <i>Antiviral Research</i> , 2016, 134, 182-191.	1.9	3
46	Preclinical pharmacokinetics comparison between resveratrol 2-hydroxypropyl- $\beta$ -cyclodextrin complex and resveratrol suspension after oral administration. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2016, 86, 263-271.	0.9	12
47	Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging. <i>International Journal of Cancer</i> , 2016, 139, 404-413.	2.3	9
48	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. <i>Oncolmmunology</i> , 2016, 5, e1253653.	2.1	30
49	Angiotenin like-1 is a novel component of the N-cadherin complex affecting endothelial/pericyte interaction in normal and tumor angiogenesis. <i>Scientific Reports</i> , 2016, 6, 30622.	1.6	22
50	A plant-expressed conjugate vaccine breaks CD4 <sup>+</sup> tolerance and induces potent immunity against metastatic Her2 <sup>+</sup> breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1166323.	2.1	36
51	Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 62-72.	0.4	93
52	Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer. <i>Oncolmmunology</i> , 2016, 5, e1082705.	2.1	9
53	The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2 <sup>+</sup> mammary cancer. <i>Plant Biotechnology Journal</i> , 2016, 14, 153-159.	4.1	12
54	L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. <i>Oncotarget</i> , 2016, 7, 66713-66727.	0.8	54

#	ARTICLE	IF	CITATIONS
55	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. <i>Oncotarget</i> , 2016, 7, 33081-33095.	0.8	15
56	Novel insights into Notum and glypicans regulation in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 41237-41257.	0.8	50
57	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	2.1	38
58	Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
59	The importance of comparative oncology in translational medicine. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 137-148.	2.0	34
60	Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. <i>Nanoscale</i> , 2015, 7, 6527-6533.	2.8	67
61	Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. <i>Magnetic Resonance Imaging</i> , 2015, 33, 725-736.	1.0	34
62	Antitumor immunization of mothers delays tumor development in cancer-prone offspring. <i>Oncolmmunology</i> , 2015, 4, e1005500.	2.1	12
63	Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1333-1343.	1.6	42
64	2H,3H-Decafluoropentane-Based Nanodroplets: New Perspectives for Oxygen Delivery to Hypoxic Cutaneous Tissues. <i>PLoS ONE</i> , 2015, 10, e0119769.	1.1	39
65	Abstract 3553: xCT is a new cancer stem cell immunotherapeutic target for breast cancer. , 2015, , .		0
66	A Mathematical-Biological Joint Effort to Investigate the Tumor-Initiating Ability of Cancer Stem Cells. <i>PLoS ONE</i> , 2014, 9, e106193.	1.1	12
67	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
68	Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth. <i>Oncolmmunology</i> , 2014, 3, e27259.	2.1	1
69	Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	22
70	Imaging DNA Damage Allows Detection of Preneoplasia in the BALB-neuT Model of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 2026-2031.	2.8	13
71	Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. <i>Journal of Immunology</i> , 2014, 192, 5434-5441.	0.4	16
72	Xenogene vaccination in the therapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1427-1442.	1.4	16

#	ARTICLE	IF	CITATIONS
73	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. <i>Clinical Cancer Research</i> , 2014, 20, 3753-3762.	3.2	64
74	Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies. <i>Leukemia</i> , 2014, 28, 941-944.	3.3	14
75	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014, 16, R10.	2.2	27
76	Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2910-2921.	3.2	24
77	Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4. <i>FASEB Journal</i> , 2014, 28, 416-429.	0.2	31
78	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 99-122.	0.7	10
79	Ultrasound-activated decafluoropentane-cored and chitosan-shelled nanodroplets for oxygen delivery to hypoxic cutaneous tissues. <i>RSC Advances</i> , 2014, 4, 38433-38441.	1.7	39
80	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. <i>BMC Genomics</i> , 2014, 15, S1.	1.2	20
81	Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. <i>Journal of Translational Medicine</i> , 2014, 12, 122.	1.8	15
82	DNA vaccination against membrane-bound Kit ligand: A new approach to inhibiting tumour growth and angiogenesis. <i>European Journal of Cancer</i> , 2014, 50, 234-246.	1.3	6
83	Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo. , 2014, , .		2
84	State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?. <i>BMC Bioinformatics</i> , 2013, 14, S2.	1.2	56
85	Multi-level model for the investigation of oncoantigen-driven vaccination effect. <i>BMC Bioinformatics</i> , 2013, 14, S11.	1.2	11
86	The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. <i>FASEB Journal</i> , 2013, 27, 4731-4744.	0.2	78
87	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. <i>Gastroenterology</i> , 2013, 144, 1098-1106.	0.6	104
88	Optical imaging detection of microscopic mammary cancer in ErbB2 transgenic mice through the DA364 probe binding via integrins. <i>Contrast Media and Molecular Imaging</i> , 2013, 8, 350-360.	0.4	11
89	miR-135b Coordinates Progression of ErbB2-Driven Mammary Carcinomas through Suppression of MID1 and MTCH2. <i>American Journal of Pathology</i> , 2013, 182, 2058-2070.	1.9	52
90	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013, 12, 1449-1463.	2.0	11

#	ARTICLE	IF	CITATIONS
91	State-of-the-Art Fusion-Finder Algorithms Sensitivity and Specificity. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	79
92	Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. <i>Frontiers in Oncology</i> , 2013, 3, 122.	1.3	27
93	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. <i>Oncolmmunology</i> , 2013, 2, e26137.	2.1	27
94	ErbB2 Receptor Over-Expression Improves Post-Traumatic Peripheral Nerve Regeneration in Adult Mice. <i>PLoS ONE</i> , 2013, 8, e56282.	1.1	23
95	DNA vaccination against oncoantigens. <i>Oncolmmunology</i> , 2012, 1, 316-325.	2.1	34
96	Digging in the RNA-seq Garbage: Evaluating the Characteristics of Unmapped RNA-seq Reads in Normal Tissues. , 2012, , .		1
97	IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1473-1484.	2.0	4
98	A vaccine targeting angiominin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. <i>Angiogenesis</i> , 2012, 15, 305-316.	3.7	35
99	Abstract 1196: Identification of lung cancer associated oncoantigens as targets for active immunotherapy. , 2012, , .		0
100	A pipeline to detect antibody-targetable cancer stem cell proteins.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13527-e13527.	0.8	0
101	BALB-neuT Female Mice as a Dynamic Model of Mammary Cancer. , 2012, , 139-166.		1
102	Vaccines and Other Immunological Approaches for Cancer Immunoprevention. <i>Current Drug Targets</i> , 2011, 12, 1957-1973.	1.0	39
103	Chondroitin sulfate proteoglycan-4: A biomarker and a potential immunotherapeutic target for canine malignant melanoma. <i>Veterinary Journal</i> , 2011, 190, e26-e30.	0.6	37
104	Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. <i>Biochemical Pharmacology</i> , 2011, 82, 1079-1089.	2.0	12
105	A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions. <i>Archives of Virology</i> , 2011, 156, 587-595.	0.9	26
106	2011: the immune hallmarks of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 319-326.	2.0	316
107	Cancer stem cell based adjuvant for oncoantigen-driven vaccination. , 2011, , .		0
108	A DNA Vaccine against ERBB2 Impairs Chemical Carcinogenesis in Random-Bred Hamsters. <i>Cancer Prevention Research</i> , 2011, 4, 994-1001.	0.7	6



#	ARTICLE	IF	CITATIONS
109	Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. <i>Cancers</i> , 2011, 3, 3225-3241.	1.7	21
110	Oncoantigens for an immune prevention of cancer. <i>American Journal of Cancer Research</i> , 2011, 1, 255-264.	1.4	4
111	Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB2 oncogene. <i>Molecular Carcinogenesis</i> , 2010, 49, 114-120.	1.3	29
112	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2803-2815.	1.6	228
113	Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of Cten. <i>Cancer Research</i> , 2010, 70, 2558-2567.	0.4	131
114	ErbB2 DNA Vaccine Combined with Regulatory T Cell Deletion Enhances Antibody Response and Reveals Latent Low-Avidity T Cells: Potential and Limits of Its Therapeutic Efficacy. <i>Journal of Immunology</i> , 2010, 184, 6124-6132.	0.4	27
115	Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity Engendered by a Kinase-Inactive Human HER2 Adenovirus-Based Vaccination Mediates Resistance to Breast Tumors. <i>Cancer Research</i> , 2010, 70, 7431-7441.	0.4	24
116	Attenuation of PI3K/Akt-Mediated Tumorigenic Signals through PTEN Activation by DNA Vaccine-Induced Anti-ErbB2 Antibodies. <i>Journal of Immunology</i> , 2010, 184, 4170-4177.	0.4	19
117	A Better Immune Reaction to ErbB-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins. <i>Cancer Research</i> , 2010, 70, 2604-2612.	0.4	54
118	Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. <i>International Journal of Cancer</i> , 2009, 124, 150-156.	2.3	28
119	Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1685-1694.	2.0	13
120	DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. <i>Cancer Gene Therapy</i> , 2008, 15, 108-114.	2.2	30
121	Targeting CD4+ CD25+ FOXP3+ Treg cells abrogates established mechanisms of immune tolerance, reshuffles the T cell repertoire and results in effective anti-tumor immunity. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 167-168.	2.2	1
122	SCA-1 Identifies the Tumor-Initiating Cells in Mammary Tumors of BALB-neuT Transgenic Mice. <i>Neoplasia</i> , 2008, 10, 1433-1443.	2.3	75
123	DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 6933-6943.	3.2	23
124	Protective Immunity Against Neu-Positive Carcinomas Elicited by Electroporation of Plasmids Encoding Decreasing Fragments of Rat Neu Extracellular Domain. <i>Human Gene Therapy</i> , 2008, 19, 229-240.	1.4	21
125	Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti-neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice. <i>Cancer Research</i> , 2008, 68, 7530-7540.	0.4	32
126	ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary Carcinomas. <i>Current Protocols in Immunology</i> , 2008, 82, Unit 20.9.1-20.9-10.	3.6	41



#	ARTICLE	IF	CITATIONS
127	Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice. <i>Current Cancer Drug Targets</i> , 2008, 8, 230-242.	0.8	13
128	Requirement for IFN- $\beta$ , CD8+ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu+ Tumors. <i>Cancer Research</i> , 2007, 67, 6425-6432.	0.4	36
129	Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. <i>Breast Cancer Research</i> , 2007, 9, 211.	2.2	38
130	Are oncoantigens suitable targets for anti-tumour therapy?. <i>Nature Reviews Cancer</i> , 2007, 7, 707-713.	12.8	55
131	p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. <i>EMBO Journal</i> , 2007, 26, 2843-2855.	3.5	83
132	Vaccination for Treatment and Prevention of Cancer in Animal Models. <i>Advances in Immunology</i> , 2006, 90, 175-213.	1.1	75
133	Vaccines for tumour prevention. <i>Nature Reviews Cancer</i> , 2006, 6, 204-216.	12.8	312
134	Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice. <i>Journal of Immunology</i> , 2006, 177, 7626-7633.	0.4	71
135	Immunosurveillance of ErbB2 Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-Tolerance. <i>Cancer Research</i> , 2006, 66, 7734-7740.	0.4	73
136	A DNA vaccine targeting angiominin inhibits angiogenesis and suppresses tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9208-9213.	3.3	77
137	Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression. <i>Journal of Immunology</i> , 2006, 176, 7695-7703.	0.4	19
138	p130Cas as a New Regulator of Mammary Epithelial Cell Proliferation, Survival, and HER2-Neu Oncogene-Dependent Breast Tumorigenesis. <i>Cancer Research</i> , 2006, 66, 4672-4680.	0.4	123
139	Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas. <i>British Journal of Cancer</i> , 2005, 93, 1250-1256.	2.9	6
140	An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. <i>BMC Bioinformatics</i> , 2005, 6, S7.	1.2	27
141	Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. <i>International Journal of Cancer</i> , 2005, 113, 67-77.	2.3	47
142	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 599-610.	2.0	14
143	Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity. <i>Clinical Cancer Research</i> , 2005, 11, 1941-1952.	3.2	62
144	Cancer immunoprevention. <i>Future Oncology</i> , 2005, 1, 57-66.	1.1	43

#	ARTICLE	IF	CITATIONS
145	Immunotherapy and immunoprevention of cancer: where do we stand?. Expert Opinion on Biological Therapy, 2005, 5, 717-726.	1.4	6
146	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. American Journal of Pathology, 2005, 166, 1205-1216.	1.9	43
147	The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine, 2005, 23, 3280-3287.	1.7	17
148	Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Research, 2005, 65, 1071-8.	0.4	33
149	Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice. Cancer Research, 2004, 64, 2858-2864.	0.4	143
150	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. Cancer Research, 2004, 64, 4001-4009.	0.4	87
151	Toward a Long-Lasting Immune Prevention of HER2 Mammary Carcinomas: Directions from Transgenic Mice. Cell Cycle, 2004, 3, 702-704.	1.3	7
152	Immunological inhibition of carcinogenesis. Cancer Immunology, Immunotherapy, 2004, 53, 204-216.	2.0	30
153	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. Journal of Clinical Investigation, 2004, 113, 709-717.	3.9	64
154	Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice. Cell Cycle, 2004, 3, 704-6.	1.3	4
155	Immunological prevention of spontaneous tumors: a new prospect?. Immunology Letters, 2002, 80, 75-79.	1.1	16
156	IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk. Journal of Immunology, 2001, 166, 3890-3899.	0.4	157
157	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. Journal of Experimental Medicine, 2001, 194, 1195-1206.	4.2	218
158	Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. British Journal of Cancer, 1999, 79, 770-779.	2.9	18
159	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. Journal of Experimental Medicine, 1998, 188, 589-596.	4.2	291
160	Cytokines and Tumor Immunogenicity. , 1998, , 231-247.		1
161	Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12. Journal of the National Cancer Institute, 1997, 89, 1049-1058.	3.0	158
162	Constitutive expression of lymphoma-associated NFkB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene, 1997, 14, 1805-1810.	2.6	42

#	ARTICLE	IF	CITATIONS
163	Cytokines, tumour-cell death and immunogenicity: a question of choice. Trends in Immunology, 1997, 18, 32-36.	7.5	161
164	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. European Journal of Immunology, 1996, 26, 1851-1859.	1.6	52
165	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. European Journal of Immunology, 1995, 25, 1154-1162.	1.6	111
166	Systemic effects of cytokines released by gene-transduced tumor cells: Marked hyperplasia induced in small bowel by $\hat{I}^3$ -interferon transfectants through host lymphocytes. International Journal of Cancer, 1995, 61, 425-430.	2.3	12
167	Transduction of Genes Coding for a Histocompatibility (MHC) Antigen and for Its Physiological Inducer Interferon- $\hat{I}^3$ in the Same Cell: Efficient MHC Expression and Inhibition of Tumor and Metastasis Growth. Human Gene Therapy, 1995, 6, 743-752.	1.4	23
168	Genotypic, Phenotypic and Biological Characterization of a Novel Human Lung Adenocarcinoma Cell Line (LC 89). Oncology, 1994, 51, 220-223.	0.9	5
169	Inhibition of tumor growth and enhancement of metastasis after transfection of the $\hat{I}^3$ -interferon gene. International Journal of Cancer, 1993, 55, 320-329.	2.3	89
170	Cytokine-Induced Tumor Immunogenicity: From Exogenous Cytokines to Gene Therapy. Journal of Immunotherapy, 1993, 14, 253-257.	1.2	24
171	Tumor Immunogenicity Induced by the Local Occurrence of Il-2. , 1993, , 31-37.		0
172	Strategies for cytokine utilisation in tumor therapy. Medical Oncology and Tumor Pharmacotherapy, 1993, 10, 53-59.	1.0	6
173	From exogenous cytokines to gene therapy: Cytokine activated tumor inhibition.. Pharmacological Research, 1992, 26, 48-49.	3.1	0
174	A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 1992, 70, 93-104.	13.5	1,348